Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Cited by (1,078)

Items 1,001–1,078 of 1,078

1. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials
   Costa, Ricardo, Carneiro, Benedito A., Agulnik, Mark, Rademaker, Alfred W., Pai, Sachin G., Villaflor, Victoria M., Cristofanilli, Massimo, Sosman, Jeffrey A., Giles, Francis J. · 2017 · Oncotarget
2. Clinical pharmacology considerations for the development of immune checkpoint inhibitors
   Sheng, Jennifer, Srivastava, Shivani, Sanghavi, Kinjal, Lu, Zheng, Schmidt, Brian J., Bello, Akintunde, Gupta, Manish · 2017 · The Journal of Clinical Pharmacology
3. Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
   Du, Xuexiang, Liu, Mingyue, Su, Juanjuan, Zhang, Peng, Tang, Fei, Ye, Peiying, Devenport, Martin, Wang, Xu, Zhang, Yan, Liu, Yang et al. · 2018 · Cell Research
4. Opportunities for Small Molecules in Cancer Immunotherapy
   van der Zanden, Sabina Y., Luimstra, Jolien J., Neefjes, Jacques, Borst, Jannie, Ovaa, Huib · 2020 · Trends in Immunology
5. Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy
   Zhu, Bo, Tang, Liming, Chen, Shuyang, Yin, Chengqian, Peng, Shiguang, Li, Xin, Liu, Tongzheng, Liu, Wei, Han, Changpeng, Stawski, Lukasz et al. · 2018 · Oncogene
6. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
   Shi, Lewis Zhichang, Fu, Tihui, Guan, Baoxiang, Chen, Jianfeng, Blando, Jorge M., Allison, James P., Xiong, Liangwen, Subudhi, Sumit K., Gao, Jianjun, Sharma, Padmanee · 2016 · Nature Communications
7. Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade
   Lander, Varintra E., Belle, Jad I., Kingston, Natalie L., Herndon, John M., Hogg, Graham D., Liu, Xiuting, Kang, Liang-I, Knolhoff, Brett L., Bogner, Savannah J., Baer, John M. et al. · 2022 · Cancer Discovery
8. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients
   Wistuba-Hamprecht, Kilian, Martens, Alexander, Heubach, Florian, Romano, Emanuela, Geukes Foppen, Marnix, Yuan, Jianda, Postow, Michael, Wong, Phillip, Mallardo, Domenico, Schilling, Bastian et al. · 2017 · European Journal of Cancer
9. Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients
   Lee, Hansol, Quek, Camelia, Silva, Ines, Tasker, Annie, Batten, Marcel, Rizos, Helen, Lim, Su Yin, Nur Gide, Tuba, Shang, Ping, Attrill, Grace H. et al. · 2019 · OncoImmunology
10. IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
    Johnson, Daniel, Patel, Anisha B., Uemura, Marc I., Trinh, Van A., Jackson, Natalie, Zobniw, Chrystia M., Tetzlaff, Michael T., Hwu, Patrick, Curry, Jonathan L., Diab, Adi · 2019 · Cancer Immunology Research
11. Combination therapeutics in complex diseases
    He, Bing, Lu, Cheng, Zheng, Guang, He, Xiaojuan, Wang, Maolin, Chen, Gao, Zhang, Ge, Lu, Aiping · 2016 · Journal of Cellular and Molecular Medicine
12. PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations
    Scheel, Andreas H., Ansén, Sascha, Schultheis, Anne M., Scheffler, Matthias, Fischer, Rieke N., Michels, Sebastian, Hellmich, Martin, George, Julie, Zander, Thomas, Brockmann, Michael et al. · 2016 · OncoImmunology
13. Autoimmune endocrine dysfunctions associated with cancer immunotherapies
    Ferrari, Silvia Martina, Fallahi, Poupak, Elia, Giusy, Ragusa, Francesca, Ruffilli, Ilaria, Patrizio, Armando, Galdiero, Maria Rosaria, Baldini, Enke, Ulisse, Salvatore, Marone, Gianni et al. · 2019 · International Journal of Molecular Sciences
14. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
    Botti, Gerardo, Fratangelo, Federica, Cerrone, Margherita, Liguori, Giuseppina, Cantile, Monica, Anniciello, Anna Maria, Scala, Stefania, D’Alterio, Crescenzo, Trimarco, Chiara, Ianaro, Angela et al. · 2017 · Journal of Translational Medicine
15. Assessing the future of solid tumor immunotherapy
    Guha, Prajna, Heatherton, Kara R., O’Connell, Kyle P., Alexander, Ian S., Katz, Steven C. · 2022 · Biomedicines
16. Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management
    Samaan, Mark A., Pavlidis, Polychronis, Papa, Sophie, Powell, Nick, Irving, Peter M. · 2018 · Nature Reviews Gastroenterology & Hepatology
17. Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study
    Gogas, H., Dréno, B., Larkin, J., Demidov, L., Stroyakovskiy, D., Eroglu, Z., Francesco Ferrucci, P., Pigozzo, J., Rutkowski, P., Mackiewicz, J. et al. · 2021 · Annals of Oncology
18. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
    Yu, Jiayi, Yan, Junya, Guo, Qian, Chi, Zhihong, Tang, Bixia, Zheng, Bin, Yu, Jinyu, Yin, Ting, Cheng, Zhiyuan, Wu, Xiaowen et al. · 2019 · Clinical Cancer Research
19. Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer
    Karayama, M., Masuda, J., Mori, K., Yasui, H., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., Nakamura, Y. et al. · 2021 · Clinical and Translational Oncology
20. Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics
    Frey, Nina, Venturelli, Sascha, Zender, Lars, Bitzer, Michael · 2018 · Nature Reviews Gastroenterology & Hepatology
21. Cardiotoxicity of Anticancer Therapeutics
    Dong, Jerry, Chen, Hong · 2018 · Frontiers in Cardiovascular Medicine
22. Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study
    Okada, Naoto, Kawazoe, Hitoshi, Takechi, Kenshi, Matsudate, Yoshihiro, Utsunomiya, Ryo, Zamami, Yoshito, Goda, Mitsuhiro, Imanishi, Masaki, Chuma, Masayuki, Hidaka, Noriaki et al. · 2019 · Clinical Therapeutics
23. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer
    Alemohammad, Hajar, Najafzadeh, Basira, Asadzadeh, Zahra, Baghbanzadeh, Amir, Ghorbaninezhad, Farid, Najafzadeh, Arezoo, Safarpour, Hossein, Bernardini, Renato, Brunetti, Oronzo, Sonnessa, Margherita et al. · 2022 · Biomedicine & Pharmacotherapy
24. Product review: Avelumab, an anti-PD-L1 antibody
    Collins, Julie M., Gulley, James L. · 2019 · Human Vaccines & Immunotherapeutics
25. A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing
    Lizotte, Patrick H., Hong, Ruey-Long, Luster, Troy A., Cavanaugh, Megan E., Taus, Luke J., Wang, Stephen, Dhaneshwar, Abha, Mayman, Naomi, Yang, Aaron, Kulkarni, Meghana et al. · 2018 · Cancer Immunology Research
26. Immune-mediated drug-induced liver injury: immunogenetics and experimental models
    Gerussi, Alessio, Natalini, Ambra, Antonangeli, Fabrizio, Mancuso, Clara, Agostinetto, Elisa, Barisani, Donatella, Di Rosa, Francesca, Andrade, Raul, Invernizzi, Pietro · 2021 · International Journal of Molecular Sciences
27. Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
    Davar, Diwakar, Wang, Hong, Chauvin, Joe-Marc, Pagliano, Ornella, Fourcade, Julien J., Ka, Mignane, Menna, Carmine, Rose, Amy, Sander, Cindy, Borhani, Amir A. et al. · 2018 · Journal of Clinical Oncology
28. Opportunities and challenges in combination gene cancer therapy
    Nastiuk, Kent L., Krolewski, John J. · 2016 · Advanced Drug Delivery Reviews
29. Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma: A Review
    George, Saby, Rini, Brian I., Hammers, Hans J. · 2019 · JAMA Oncology
30. Single-cell sequencing reveals trajectory of tumor-infiltrating lymphocyte states in pancreatic cancer
    Schalck, Aislyn, Sakellariou-Thompson, Donastas, Forget, Marie-Andrée, Sei, Emi, Hughes, Tara G., Reuben, Alexandre, Bai, Shanshan, Hu, Min, Kumar, Tapsi, Hurd, Mark W. et al. · 2022 · Cancer Discovery
31. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities
    Cousin, Sophie, Italiano, Antoine · 2016 · Clinical Cancer Research
32. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects
    Urner-Bloch, U., Urner, M., Jaberg-Bentele, N., Frauchiger, A.L., Dummer, R., Goldinger, S.M. · 2016 · European Journal of Cancer
33. Vitamin E δ-tocotrienol triggers endoplasmic reticulum stress-mediated apoptosis in human melanoma cells
    Montagnani Marelli, Marina, Marzagalli, Monica, Moretti, Roberta M., Beretta, Giangiacomo, Casati, Lavinia, Comitato, Raffaella, Gravina, Giovanni L., Festuccia, Claudio, Limonta, Patrizia · 2016 · Scientific Reports
34. Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining “Actionability” of a Molecular Lesion and Patient Management Support
    Chae, Young Kwang, Pan, Alan P., Davis, Andrew A., Patel, Sandip P., Carneiro, Benedito A., Kurzrock, Razelle, Giles, Francis J. · 2017 · Molecular Cancer Therapeutics
35. Trial watch: immune checkpoint blockers for cancer therapy
    Vanpouille-Box, Claire, Lhuillier, Claire, Bezu, Lucillia, Aranda, Fernando, Yamazaki, Takahiro, Kepp, Oliver, Fucikova, Jitka, Spisek, Radek, Demaria, Sandra, Formenti, Silvia C. et al. · 2017 · OncoImmunology
36. Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials
    Kanjanapan, Y., Day, D., Butler, M.O., Wang, L., Joshua, A.M., Hogg, D., Leighl, N.B., Razak, A.R. Abdul, Hansen, A.R., Boujos, S. et al. · 2019 · European Journal of Cancer
37. Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
    Zhang, Chaoxu, Fan, Yibo, Che, Xiaofang, Zhang, Min, Li, Zhi, Li, Ce, Wang, Shuo, Wen, Ti, Hou, Kezuo, Shao, Xinye et al. · 2020 · Frontiers in Oncology
38. Scientific rationale for combination immunotherapy of hepatocellular carcinoma with anti–PD-1/PD-L1 and anti–CTLA-4 antibodies
    Kudo, Masatoshi · 2019 · Liver Cancer
39. Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma
    Angell, Trevor E., Min, Le, Wieczorek, Tad J., Hodi, F. Stephen · 2018 · Genes & Diseases
40. Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells
    Lai, Qi, Wang, Haiyong, Li, Angui, Xu, Yinhui, Tang, Liang, Chen, Qiang, Zhang, Chunfang, Gao, Yang, Song, Jianfei, Du, Zhenzong · 2018 · Oncogene
41. Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
    Cai, Xin, Zhan, Huajie, Ye, Yuguang, Yang, Jinjin, Zhang, Minghui, Li, Jing, Zhuang, Yuan · 2021 · Frontiers in Genetics
42. Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab
    Baxi, Vipul, Lee, George, Duan, Chunzhe, Pandya, Dimple, Cohen, Daniel N., Edwards, Robin, Chang, Han, Li, Jun, Elliott, Hunter, Pokkalla, Harsha et al. · 2022 · Modern Pathology
43. Adverse events associated with immune checkpoint inhibitor treatment for cancer
    Esfahani, Khashayar, Meti, Nicholas, Miller, Wilson H., Hudson, Marie · 2019 · Canadian Medical Association Journal
44. Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors
    Hollebecque, Antoine, Chung, Hyun C., de Miguel, Maria J., Italiano, Antoine, Machiels, Jean-Pascal, Lin, Chia-Chi, Dhani, Neesha C., Peeters, Marc, Moreno, Victor, Su, Wu-Chou et al. · 2021 · Clinical Cancer Research
45. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
    Lelliott, Emily J., McArthur, Grant A., Oliaro, Jane, Sheppard, Karen E. · 2021 · Frontiers in Immunology
46. Immune checkpoint inhibitors in older adults
    Elias, Rawad, Morales, Joshua, Rehman, Yasser, Khurshid, Humera · 2016 · Current Oncology Reports
47. Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome
    Mirza, Sayeef, Hill, Ebone’, Ludlow, Steven P., Nanjappa, Sowmya · 2017 · Melanoma Research
48. Checkpoint immunotherapy in pediatrics: here, gone, and back again
    Long, Adrienne H., Morgenstern, Daniel A., Leruste, Amaury, Bourdeaut, Franck, Davis, Kara L. · 2022 · American Society of Clinical Oncology Educational Book
49. Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
    Berezhnoy, Alexey, Sumrow, Bradley J., Stahl, Kurt, Shah, Kalpana, Liu, Daorong, Li, Jonathan, Hao, Su-Shin, De Costa, Anushka, Kaul, Sanjeev, Bendell, Johanna et al. · 2020 · Cell Reports Medicine
50. Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
    Abdel-Rahman, O., Helbling, D., Schmidt, J., Petrausch, U., Giryes, A., Mehrabi, A., Schöb, O., Mannhart, M., Oweira, H. · 2017 · Clinical Oncology
51. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
    Jo, Wonyoung, Won, Taejoon, Daoud, Abdel, Čiháková, Daniela · 2024 · Frontiers in Immunology
52. Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
    Roy, Dia, Gilmour, Cassandra, Patnaik, Sachin, Wang, Li Lily · 2023 · Frontiers in Immunology
53. Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
    Boland, Patrick, Pavlick, Anna C, Weber, Jeffrey, Sandigursky, Sabina · 2020 · Journal for ImmunoTherapy of Cancer
54. Managing Adverse Events With Immune Checkpoint Agents
    Dadu, Ramona, Zobniw, Chrystia, Diab, Adi · 2016 · The Cancer Journal
55. T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model
    Llewellyn, Heather P., Arat, Seda, Gao, Jingjin, Wen, Ji, Xia, Shuhua, Kalabat, Dalia, Oziolor, Elias, Virgen-Slane, Richard, Affolter, Timothy, Ji, Changhua · 2021 · Journal of Hepatology
56. A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors
    Abdel-Rahman, Omar, Fouad, Mona · 2016 · Immunotherapy
57. Immune checkpoint inhibitors for multiple myeloma immunotherapy
    Liu, Zhaoyun, Xu, Xintong, Liu, Hui, Zhao, Xianghong, Yang, Chun, Fu, Rong · 2023 · Experimental Hematology & Oncology
58. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma
    Tetzlaff, M.T., Adhikari, C., Lo, S., Rawson, R.V., Amaria, R.N., Menzies, A.M., Wilmott, J.S., Ferguson, P.M., Ross, M.I., Spillane, A.J. et al. · 2020 · Annals of Oncology
59. Epigenetic mechanisms of tumor resistance to immunotherapy
    Arenas-Ramirez, Natalia, Sahin, Dilara, Boyman, Onur · 2018 · Cellular and Molecular Life Sciences
60. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto’s disease and diabetes mellitus: a case report
    Yonezaki, Kazuko, Kobayashi, Toshihiro, Imachi, Hitomi, Yoshimoto, Takuo, Kikuchi, Fumi, Fukunaga, Kensaku, Sato, Seisuke, Ibata, Tomohiro, Yamaji, Nao, Lyu, Jingya et al. · 2018 · Journal of Medical Case Reports
61. Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response
    Felix, Joana, Lambert, Jérome, Roelens, Marie, Maubec, Eve, Guermouche, Hélène, Pages, Cécile, Sidina, Irina, Cordeiro, Debora J., Maki, Guitta, Chasset, François et al. · 2016 · OncoImmunology
62. Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control
    Hughes, Michael S., Zheng, Hui, Zubiri, Leyre, Molina, Gabriel E., Chen, Steven T., Mooradian, Meghan J., Allen, Ian M., Reynolds, Kerry L., Dougan, Michael · 2019 · Cancer Medicine
63. Statistical controversies in clinical research: comparison of primary outcomes in protocols, public clinical-trial registries and publications: the example of oncology trials
    Perlmutter, A.S., Tran, V.-T., Dechartres, A., Ravaud, P. · 2017 · Annals of Oncology
64. Impact of Age-, Cancer- and Treatment-Driven Inflammation on T Cell Function and Immunotherapy
    Quinn, Kylie M, Kartikasari, Apriliana E R, Cooke, Rachel E, Koldej, Rachel M, Ritchie, David S, Plebanski, Magdalena · 2020 · Journal of Leukocyte Biology
65. Immunotherapy in Glioblastoma: A Clinical Perspective
    Desbaillets, Nicolas, Hottinger, Andreas Felix · 2021 · Cancers
66. Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
    Hoefsmit, Esmée P., Rozeman, Elisa A., Haanen, John B.A.G., Blank, Christian U. · 2019 · ESMO Open
67. CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
    Sanborn, Rachel E, Hamid, Omid, de Vries, Elisabeth GE, Ott, Patrick A, Garcia-Corbacho, Javier, Boni, Valentina, Bendell, Johanna, Autio, Karen A, Cho, Daniel C, Plummer, Ruth et al. · 2021 · Journal for ImmunoTherapy of Cancer
68. ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
    Kyte, J. A., Røssevold, A., Falk, R. S., Naume, B. · 2020 · Journal of Translational Medicine
69. How does the gut microbiome influence immune checkpoint blockade therapy?
    Almonte, Andrew A, Rangarajan, Hareesha, Yip, Desmond, Fahrer, Aude M · 2021 · Immunology & Cell Biology
70. Activation of CD8(+) T cells contributes to antitumor effects of CDK4/6 inhibitors plus MEK inhibitors
    Teh, Jessica L.F., Erkes, Dan A., Cheng, Phil F., Tiago, Manoela, Wilski, Nicole A., Field, Conroy O., Chervoneva, Inna, Levesque, Mitch P., Xu, Xiaowei, Dummer, Reinhard et al. · 2020 · Cancer Immunology Research
71. Acral melanoma in skin of color: current insights and future directions: a narrative review
    Nadelmann, Emily, Singh, Ajay, Abbruzzese, Matteo, Adeuyan, Oluwaseyi, Kenchappa, Divya, Kovrizhkin, Katherine, Lightman, Michelle, Samouha, Avishai, Tao, Kevin, Yun, Jaewon et al. · 2025 · Cancers
72. Microbiota-centered interventions to boost immune checkpoint blockade therapies
    Almonte, Andrew A., Thomas, Simon, Zitvogel, Laurence · 2025 · Journal of Experimental Medicine
73. irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets
    Bejan, Cosmin A., Wang, Michelle, Venkateswaran, Sriram, Bergmann, Ewa A., Hiles, Laura, Xu, Yaomin, Chandler, G Scott, Brondfield, Sam, Silverstein, Jordyn, Wright, Francis et al. · 2026 · eBioMedicine
74. Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients
    Machado, Marina Amaral de Ávila, de Moura, Cristiano Soares, Chan, Kelvin, Curtis, Jeffrey R., Hudson, Marie, Abrahamowicz, Michal, Jamal, Rahima, Pilote, Louise, Bernatsky, Sasha · 2020 · Scientific Reports
75. Gut microbiota diversity and composition in predicting immunotherapy response and immunotherapy-related colitis in melanoma patients: A systematic review
    Oey, Oliver, Liu, Yu-Yang, Sunjaya, Angela Felicia, Simadibrata, Daniel Martin, Khattak, Muhammad Adnan, Gray, Elin · 2022 · World Journal of Clinical Oncology
76. Case Report: Dual Checkpoint Inhibition in Advanced Metastatic Osteosarcoma Results in Remission of All Tumor Manifestations—A Report of a Stunning Success in a 37-Year-Old Patient
    Sterz, Ulrich, Grube, Matthias, Herr, Wolfgang, Menhart, Karin, Wendl, Christina, Vogelhuber, Martin · 2021 · Frontiers in Oncology
77. Successful use of adalimumab in immune checkpoint inhibitor-associated inflammatory arthritis
    Oke, Anuoluwapo R, Wheater, Matthew, Karydis, Ioannis, Wallis, Dinny · 2018 · Rheumatology Advances in Practice
78. Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients
    Gauci, Marie-Léa, Boudou, Philippe, Squara, Pierre-Alexandre, Delyon, Julie, Allayous, Clara, Mourah, Samia, Resche-Rigon, Matthieu, Lebbé, Céleste, Baroudjian, Barouyr, Gautier, Jean-François · 2019 · Melanoma Research